

David A Barrington

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5247555/publications.pdf>

Version: 2024-02-01

12
papers

151
citations

1307594

7
h-index

1199594

12
g-index

12
all docs

12
docs citations

12
times ranked

184
citing authors

#	ARTICLE	IF	CITATIONS
1	Distance from a Comprehensive Cancer Center: A proxy for poor cervical cancer outcomes?. Gynecologic Oncology, 2016, 143, 617-621.	1.4	38
2	Pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis. Gynecologic Oncology, 2019, 153, 381-384.	1.4	28
3	Where you live matters: A National Cancer Database study of Medicaid expansion and endometrial cancer outcomes. Gynecologic Oncology, 2020, 158, 407-414.	1.4	16
4	Up-Front Multigene Panel Testing for Cancer Susceptibility in Patients With Newly Diagnosed Endometrial Cancer: A Multicenter Prospective Study. JCO Precision Oncology, 2021, 5, 1588-1602.	3.0	15
5	Lenvatinib plus pembrolizumab in advanced recurrent endometrial cancer: A cost-effectiveness analysis. Gynecologic Oncology, 2021, 162, 626-630.	1.4	11
6	Niraparib maintenance in frontline management of ovarian cancer: a cost effectiveness analysis. International Journal of Gynecological Cancer, 2020, 30, 1569-1575.	2.5	10
7	More than treatment refusal: a National Cancer Database analysis of adjuvant treatment refusal and racial survival disparities among women with endometrial cancer. American Journal of Obstetrics and Gynecology, 2022, 227, 244.e1-244.e17.	1.3	8
8	Differences in referral patterns based on race for women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic. Gynecologic Oncology, 2019, 154, 379-382.	1.4	7
9	Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic. Gynecologic Oncology, 2018, 149, 337-340.	1.4	6
10	Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis. Gynecologic Oncology, 2022, 165, 500-505.	1.4	6
11	Does the addition of radiation improve survival compared to chemotherapy alone in women with stage IV endometrial carcinoma? Analysis of the NCDB and SEER databases. Gynecologic Oncology, 2022, 165, 522-529.	1.4	5
12	Less is more: Abdominal closure protocol does not reduce surgical site infection after hysterectomy. Gynecologic Oncology, 2022, 166, 69-75.	1.4	1